The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study
Authors:
- M S HeibergMHM S Heiberg
- C KaufmannCKC Kaufmann
- E RødevandERE Rødevand
- K MikkelsenKMK Mikkelsen
- W KoldingsnesWKW Koldingsnes
- P MowinckelPMP Mowinckel
- T K KvienTKT K Kvien
- 1 August 2007
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 66 (8) , 1038-1042
Abstract
To compare the response to treatment with tumour necrosis factor (TNF) inhibitors and methotrexate (MTX) monotherapy in patients with psoriatic arthritis (PsA) within a real-life clinical setting. We analysed data from an ongoing longitudinal, observational multicentre study in Norway. Our data comprised 526 cases of patients with PsA who received either anti-TNF treatment (n = 146) or MTX monotherapy (n = 380) and were followed for at least 6 months with measures of disease activity, health status and utility scores. A propensity score was computed to adjust for channelling bias. The changes in measures of disease activity and health-related quality of life from baseline to 3- and 6-month follow-up were compared between the groups with adjustments for the baseline value of the dependent variable and the propensity score (analyses of covariance (ANCOVA)). The groups were significantly different at baseline with respect to demographic and disease activity measures. The variables included in the propensity score were age, sex, number of previous disease modifying anti-rheumatic drugs (DMARDs), presence of erosive disease, treatment centre and investigator's global assessment. The adjusted changes at 6 months were significantly larger in the anti-TNF group for ESR, DAS-28, M-HAQ, patient's assessments of pain, fatigue and global disease activity on a visual analogue scale (VAS) and 4 out of 8 SF-36 dimensions. Clinical improvement was superior with TNF inhibitors compared to MTX monotherapy in patients with PsA, when assessed in this setting of daily clinical practice.Keywords
This publication has 26 references indexed in Scilit:
- Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issuesAnnals of the Rheumatic Diseases, 2004
- Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progressionArthritis & Rheumatism, 2004
- A comparison of the EQ‐5D and SF‐6D across seven patient groupsHealth Economics, 2004
- Results from controlled clinical trials: how relevant for clinical practice?2003
- A simplified disease activity index for rheumatoid arthritis for use in clinical practiceRheumatology, 2003
- The Stanford Health Assessment Questionnaire: Dimensions and Practical ApplicationsHealth and Quality of Life Outcomes, 2003
- Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies?Annals of the Rheumatic Diseases, 1999
- The MOS 36-ltem Short-Form Health Survey (SF-36): III. Tests of Data Quality, Scaling Assumptions, and Reliability Across Diverse Patient GroupsMedical Care, 1994
- Randomized, Double‐Blind, Placebo Controlled Trial of Low‐Dose Pulse Methotrexate in Psoriatic ArthritisArthritis & Rheumatism, 1984
- Assessment of patient satisfaction in activities of daily living using a modified stanford health assessment questionnaireArthritis & Rheumatism, 1983